Stocktoria
Coherus Oncology, Inc. CHRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-11-06
Coherus Oncology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -429.5% | -756.6% | -79.0% | -121.7% | -80.8% |
| Net margin | 398.4% | 108.0% | -92.5% | -138.2% | -87.9% |
| FCF margin | — | — | -68.1% | -115.2% | -11.9% |
| Return on assets | 65.0% | 6.4% | -37.8% | -60.7% | -42.3% |
| Return on equity | 275.4% | -21.6% | 123.0% | 212.3% | -293.8% |
| Current ratio | 1.47 | 1.21 | 1.43 | 2.75 | 3.64 |
| Revenue growth | 59.8% | -89.7% | 21.9% | -35.4% | -31.4% |
Source: SEC EDGAR filings · CIK 0001512762 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.